We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Prostate Biopsy Increases Risk of Hospitalization

By HospiMedica International staff writers
Posted on 05 Oct 2011
Men who underwent prostate biopsy were more than twice as likely to be hospitalized within 30 days compared with men who did not undergo the procedure, according to a new study.

Researchers at Johns Hopkins University (JHU; Baltimore, MD, USA) analyzed a 5% random sample of Medicare-linked data from the US National Cancer Institute (NCI; Bethesda, MD, USA) Surveillance, Epidemiology, and End Results (SEER) program. More...
The analysis included 17,472 men who underwent prostate biopsy from 1991 to 2007, and a random-sample control group of men who did not have the procedure. The biopsy group was slightly older (median age 73 versus 72.4), healthier, and more likely to be white. The biopsies led to prostate cancer diagnoses in 2,992 men.

The researchers found that prostate biopsy was associated with a 30-day hospitalization odds ratio of 2.65; a total of 1,209 men in the biopsy group were hospitalized within 30 days of the procedure, and for every year of the study period, hospitalization occurred more often than in the control group. Infection was the primary diagnosis in 0.38% of the biopsy group and 0.19% of the control group. Noninfectious complications also led to hospitalization significantly more often after prostate biopsy (0.30%) than in the control group (0.04%). Infectious complications leading to hospitalization rose steadily from 2000 to the end of the study period, possibly a reflection of emerging multidrug-resistant organisms. Significantly, hospitalization for biopsy-related infection increased the mortality odds 12-fold, as compared with men who did not have prostate biopsies. The study was published in the October 2011 issue of the Journal of Urology.

“Prostate biopsy is an essential procedure for detecting prostate cancers; coupled with appropriate screening, prostate biopsies save lives,” said senior author Edward Schaeffer, MD, PhD. “However, it is important for men to be aware of the possible risks of prostate biopsies, which are often described as simple outpatient procedures.”

Since prostate needle biopsy is performed with transrectal ultrasound guidance, the procedure may introduce rectal bacteria into the prostate, creating a potential for infection. Severe infection can lead to hospitalization, as can other potential complications of prostate biopsy, such as hematuria, hematochezia, and urinary retention. To decrease the risk of infection, periprocedural antibiotic prophylaxis has become routine, which unfortunately has the potential to contribute to emerging antibacterial resistance.

Related Links:

Johns Hopkins University



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.